Company intelligence / Profile preview
US WorldMeds
- Ownership
- Private
- Development stage
- Commercial
Overview
US WorldMeds is a privately held specialty pharmaceutical company focused on developing and commercializing unique healthcare products that address challenging conditions and unmet medical needs. The company has several FDA-approved drugs on the market—including IWILFIN™ as the first oral maintenance therapy to reduce relapse risk in high-risk neuroblastoma—alongside therapies targeting opioid withdrawal, hypertension, muscle disorders, and more. Their portfolio demonstrates both late-stage development success and commercial presence.[4][3][1]
- Therapeutic areas
- GastroenterologyPsychiatryCardiovascularOncologyRare DiseasesNeurology
- Modalities
- Small molecules (e.g., eflornithine, nadolol, lofexidine, dantrolene, naloxone)[2][4]
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on US WorldMeds.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on US WorldMeds.